Iconovo Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

IconovoDer Gewinn des Unternehmens wird voraussichtlich um 1.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 48.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 79.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -2.4% betragen.

Wichtige Informationen

-1.8%

Wachstumsrate der Gewinne

79.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	36.6%
Wachstumsrate der Einnahmen	48.5%
Zukünftige Eigenkapitalrendite	-2.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Gewinn- und Umsatzwachstumsprognosen

OM:ICO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	127	N/A	-11	14	2
12/31/2025	76	-23	-20	-9	2
12/31/2024	52	-13	-45	-9	2
9/30/2024	25	-40	-57	-32	N/A
6/30/2024	27	-39	-52	-29	N/A
3/31/2024	28	-42	-53	-32	N/A
12/31/2023	28	-46	-62	-39	N/A
9/30/2023	31	-53	-74	-47	N/A
6/30/2023	36	-53	-80	-51	N/A
3/31/2023	43	-52	-85	-52	N/A
12/31/2022	47	-48	-81	-44	N/A
9/30/2022	49	-40	-63	-30	N/A
6/30/2022	54	-34	-58	-24	N/A
3/31/2022	49	-28	-44	-12	N/A
12/31/2021	43	-26	-37	-11	N/A
9/30/2021	41	-22	-35	-13	N/A
6/30/2021	31	-20	-29	-11	N/A
3/31/2021	24	-20	-32	-17	N/A
12/31/2020	23	-17	-29	-16	N/A
9/30/2020	15	-20	-26	-16	N/A
6/30/2020	13	-20	-27	-18	N/A
3/31/2020	13	-16	-22	-13	N/A
12/31/2019	17	-11	-20	-12	N/A
9/30/2019	22	-2	-18	-10	N/A
6/30/2019	19	-3	-11	-3	N/A
3/31/2019	20	0	-11	-5	N/A
12/31/2018	15	-4	-6	-1	N/A
9/30/2018	21	-1	-3	2	N/A
6/30/2018	20	-2	N/A	-3	N/A
3/31/2018	23	-1	N/A	1	N/A
12/31/2017	22	1	N/A	-4	N/A
12/31/2016	18	3	N/A	6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ICO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ICO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ICO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ICODie Einnahmen des Unternehmens (48.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0.02% pro Jahr).

Hohe Wachstumseinnahmen: ICODie Einnahmen des Unternehmens (48.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ICO wird voraussichtlich in 3 Jahren unrentabel sein.

Iconovo Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 12% to kr23.50

Consensus revenue estimates increase by 17%

Consensus revenue estimates increase by 15%, EPS downgraded

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

Price target decreased by 27% to kr63.00

Price target increased to kr140

Recent updates

Iconovo AB (publ) has completed a Composite Units Offering in the amount of SEK 28.653075 million.

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock

Director recently bought kr258k worth of stock

Chief Executive Officer recently bought kr104k worth of stock

Price target increased to kr140

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Iconovo AB (publ) Announces Completion of Comparative Clinical Study of Icores Budesonide/Formoterol and Symbicort Turbuhaler

Chief Financial Officer recently bought kr53k worth of stock

Director recently bought kr78k worth of stock

No longer forecast to breakeven